The study, conducted by a team of psychiatrists and infectious disease specialists affiliated with Seoul National University College of Medicine and its affiliated hospitals, followed 1,030 patients admitted with COVID-19 to two tertiary hospitals in Seoul and Gyeonggi Province between January 2021 and December 2022. The findings, published in BMC Psychiatry, offer one of the most detailed long-term pictures yet of what delirium means for survival in this population, with follow-up extending well beyond the acute hospitalization period.

Delirium is notoriously difficult to study. It is defined clinically as an acute disturbance in attention and awareness that develops over a short period, tends to fluctuate throughout the day, and cannot be explained by a pre-existing neurocognitive disorder. To bring rigor to the diagnosis, the Korean team excluded patients with dementia diagnosed before admission, eliminating one of the most common sources of diagnostic ambiguity. Delirium was assessed using the Confusion Assessment Method, a widely validated bedside screening tool, and diagnoses were confirmed according to the criteria of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders. This dual approach—systematic screening combined with formal diagnostic criteria—strengthens confidence that the 119 patients classified as delirious (11.6 percent of the cohort) genuinely met the threshold.

The demographic and clinical profile of the cohort was typical of a seriously ill hospitalized COVID-19 population in the pandemic’s later waves. Patients had a mean age of 62.9 years, and 44.4 percent were women. Over the course of the study, 264 patients—25.8 percent of the entire cohort—died. The raw numbers told a striking story: mortality among patients who had experienced delirium reached 47.1 percent, compared with just 23.0 percent among those who had not, a difference so large that the probability of it arising by chance was less than one in a thousand. Unadjusted survival analysis reinforced the same pattern. Patients in the delirium group survived a median of 18.0 months, while those without delirium survived a median of 25.6 months, again a statistically significant gap.

But raw associations in observational data can mislead. Older, sicker patients are both more likely to become delirious and more likely to die, raising the classic question of whether delirium is a cause of death or merely a fellow traveler of frailty. To disentangle this, the researchers deployed logistic regression to identify independent risk factors for delirium and multivariable Cox proportional hazards regression to test whether delirium predicted mortality once other variables were held constant. These models adjusted for a comprehensive set of potential confounders, including age, comorbidity burden as measured by the Charlson Comorbidity Index, the severity of COVID-19 illness, and medication exposures during hospitalization.

The results of the risk-factor analysis were revealing on their own. Three characteristics independently predicted which patients would develop delirium. Each additional year of age raised the odds by roughly 3 percent, reflected in an odds ratio of 1.03 with a 95 percent confidence interval of 1.02 to 1.05. Greater COVID-19 severity carried an odds ratio of 3.41 (95 percent CI 2.56–4.53), meaning patients with more severe disease had more than triple the odds of becoming delirious. Most strikingly, patients who had been taking antipsychotic medications before admission faced odds 3.52 times higher (95 percent CI 1.44–8.63)—a finding that underscores how the pharmacological history of a patient’s brain shapes its resilience during acute systemic illness. Pre-admission antipsychotic use may serve as a proxy for pre-existing neuropsychiatric vulnerability, and it may also alter neurotransmitter systems, particularly dopaminergic and cholinergic pathways, that are central to the pathophysiology of delirium.

When the researchers turned to survival, the picture changed dramatically. After full multivariable adjustment, delirium was no longer a statistically significant independent predictor of death, with a hazard ratio of 1.33 and a confidence interval spanning unity (0.89–2.00, p = 0.16). In plain terms, once the analysis accounted for the fact that delirium tends to occur in older patients with more comorbidities and more severe COVID-19, the apparent survival penalty of delirium largely evaporated. What did independently predict mortality were the underlying forces that produce delirium in the first place: older age, a heavier burden of chronic disease, greater COVID-19 severity, and the use of opioids and antiepileptic medications during hospitalization. These drugs, often necessary for pain control and seizure management in critically ill patients, are themselves known to depress central nervous system function and are well-established pharmacological contributors to delirium.

The authors’ interpretation reframes the clinical conversation. Delirium, they argue, is best understood not as a direct determinant of mortality but as a barometer of systemic vulnerability—a manifestation of a brain under siege from infection, inflammation, hypoxia, metabolic derangement, and sedating medications. This distinction matters because it changes what clinicians should do with the information. If delirium were an independent killer, the priority would be treating the delirium itself as a life-threatening condition. If instead it is a sentinel, the priority becomes identifying, early in the hospitalization, the patients most likely to develop it—and intervening on the modifiable factors that drive both delirium and death.

That practical implication is central to the study’s conclusion. The identified risk factors—advanced age, severe disease, and pre-admission antipsychotic use—are largely recognizable at or near the time of admission, which creates a genuine window for proactive care. Strategies with evidence in general hospitalized populations include minimizing sedating medications where clinically feasible, ensuring adequate oxygenation, maintaining sleep-wake cycles, early mobilization, and involving family members in reorientation. In the COVID-19 context, where isolation measures, intensive care, and mechanical ventilation or high-flow oxygen therapy complicate every aspect of care, such non-pharmacological approaches require deliberate effort. The finding that opioids and antiepileptics were associated with mortality suggests that careful medication stewardship—regularly reviewing whether each sedating drug remains necessary—could be a particularly high-yield target.

The study’s strengths lie in its size, its multicenter design, its systematic delirium screening, and its extended follow-up, which distinguishes it from earlier work that captured only short-term in-hospital or 30-day outcomes. By demonstrating that the association between delirium and mortality persists in raw data over many months but dissolves under multivariable adjustment, the study provides a methodological caution for the field: many published claims that delirium “causes” death in acute illness may partly reflect inadequate confounder control. At the same time, the authors acknowledge limitations inherent in a retrospective design. Delirium detection depended on clinical documentation and screening practices, and hypoactive delirium—the quiet, withdrawn form that is easily missed—may have been underrecognized, potentially blurring the contrast between groups. The exclusion of patients with pre-existing dementia, while methodologically valuable, also means the findings may not generalize to the very population in which delirium is most common.

Funded by the Patient-Centered Clinical Research Coordinating Center under the Ministry of Health and Welfare of the Republic of Korea, the study adds an important piece to the evolving understanding of neuropsychiatric complications of COVID-19. Years after the acute phase of the pandemic, researchers are still mapping how the virus and the measures taken against it reshape the trajectory of vulnerable patients. This work suggests that the confused, disoriented patient in a hospital bed is not simply a psychiatric problem to be suppressed with medication, but a whole-body alarm—a signal that the patient’s physiology is failing on multiple fronts and that aggressive, thoughtful, multidisciplinary intervention may still change the long-term outcome. For clinicians managing hospitalized patients with severe infections, the message is clear: recognize delirium early, treat it as a marker of danger, and direct that vigilance toward the underlying systemic illness it reflects.

Pediatric hematopoietic stem cell transplantation, a procedure that involves the infusion of stem cells to treat various hematological disorders, is associated with a multitude of risks and potential complications. Chief among these risks is the heightened susceptibility to infections, which can arise due to the immunocompromised state of patients following the transplantation process. This study’s central objective was to analyze the trends in antimicrobial therapy and its correlation with clinical outcomes in children undergoing HSCT, offering a basis for evidence-based guidelines in clinical practice.

The backdrop of this research is the increasing global concern regarding antimicrobial resistance, which can be exacerbated by inappropriate prescribing practices. Inadequate or excessive use of antibiotics can lead to resistance, diminishing their effectiveness for future generations. As the study reveals, understanding the specifics of antimicrobial use within this vulnerable population is more pressing than ever.

The methodology employed in the study involved a comprehensive review of patient records from multiple centers across China, ensuring a diverse and representative sample. This retrospective approach allowed the researchers to collect extensive data over a significant period, comprising various demographics, treatment regimens, and clinical outcomes. By analyzing this data, they aimed to identify not just the frequency and type of antimicrobials used, but also the rationale behind their use, as well as the impact on patient health.

One of the key findings of the study was that certain patterns emerged regarding the choice of antibiotics based on factors such as age, underlying conditions, and the timing of transplantation. It became evident that pediatric patients with pre-existing conditions or those who underwent conditioning regimens prior to HSCT were more likely to receive aggressive antimicrobial therapy. This insight is critical for healthcare providers as it underlines the importance of personalized medicine in managing the complex needs of each patient.

The researchers also noted that there was a tendency towards the use of broad-spectrum antibiotics, reflecting a pragmatic approach to mitigate the risk of infections. However, the implications of such practices are concerning, and the study prompts a reevaluation of prescribing habits. The need for targeted antimicrobial therapy, especially considering the growing threat of resistance, cannot be overstated.

Moreover, the study also delves into the complications arising from antimicrobial therapy, such as adverse drug reactions and the potential impact on the patient’s overall recovery process. It was observed that while antibiotics are crucial in preventing and treating infections, their side effects can sometimes complicate an already delicate treatment pathway. The balance between effective infection management and minimizing adverse effects becomes a central theme of the researchers’ discussions.

In addition to highlighting the treatment patterns, the research candidly discusses the barriers faced by healthcare professionals in optimizing antimicrobial use. Issues such as variability in guidelines across institutions, the lack of standardized protocols, and limited access to rapid diagnostic tools contribute to these challenges. As the medical community grapples with these obstacles, the necessity for a unified approach is apparent.

Considering the implications of this study, it is essential to foster dialogues among healthcare teams to improve antimicrobial stewardship. Employing strategies such as regular audits of prescribing practices, continuous education, and the incorporation of infectious disease specialists into the care team can lead to improved patient outcomes. The researchers advocate for institutional policies that aim to standardize and optimize antibiotic use, which would ultimately benefit pediatric patients undergoing HSCT.

The healthcare landscape is evolving, and so too are the approaches to managing infections in high-risk patient populations. The findings of this study serve as a clarion call for integrating evidence-based practices into everyday clinical settings. By emphasizing the importance of monitoring antimicrobial use and fostering collaboration among healthcare providers, improved clinical outcomes are not merely a possibility but a genuine goal.

In conclusion, this retrospective study offers invaluable insights into the antimicrobial use patterns among pediatric patients undergoing hematopoietic stem cell transplantation in China. The necessity for targeted, evidence-based antimicrobial strategies has never been more critical, especially in light of the challenges posed by antimicrobial resistance. As healthcare professionals continue to navigate the complexities of treating these vulnerable patients, the findings of this research will undoubtedly serve as a foundation for future advancements in infection management.

As the study paves the way for further research and policy development, it highlights the urgency of addressing antimicrobial-related challenges in pediatric care. When we equip ourselves with knowledge and adopt a proactive stance towards antimicrobial stewardship, we pave the way for improved health outcomes not just in China, but globally, for future generations.

Subject of Research: Antimicrobial use in pediatric hematopoietic stem cell transplantation.

Article Title: Antimicrobial use in pediatric hematopoietic stem cell transplantation in China: a retrospective multicenter cohort study.

Article References:

Cui, Y., Cheng, H., Liu, B. et al. Antimicrobial use in pediatric hematopoietic stem cell transplantation in China: a retrospective multicenter cohort study.
BMC Pediatr (2026). https://doi.org/10.1186/s12887-026-06536-9

Image Credits: AI Generated

DOI:

Keywords: Antimicrobial resistance, pediatric hematopoietic stem cell transplantation, infection management, antibiotic stewardship, healthcare challenges.

This extensive analysis reveals a concerning trend: while initial adherence following baseline screening is robust, it appears to wane annually. Such a decline underscores the necessity for ongoing engagement strategies to bolster long-term participation in lung cancer screening programs. The findings suggest that healthcare systems must prioritize adherence as not just a metric of participation but as an essential quality indicator for lung cancer screening, making it a fundamental component of cancer control strategies.

The alarming statistics emphasize the urgency of effective screening measures. Lung cancer remains a leading cause of cancer-related mortality globally, and early detection is paramount to improving prognosis. The interplay of screening frequency and healthcare disparities raises questions about access to care, patient education, and the resources available for sustaining long-term adherence. The research hints at the multifaceted challenges faced by healthcare providers in encouraging patients to remain vigilant about participating in these lifesaving programs.

Throughout the study, the importance of communication and patient engagement emerged as central themes. Healthcare providers are urged to cultivate robust dialogue with patients regarding the risks, benefits, and logistics of lung cancer screening. This two-way communication can empower patients, fostering a sense of responsibility for their health and enhancing their understanding of the critical nature of early detection. Educational initiatives should be tailored to meet the unique needs of diverse populations to combat potential barriers to adherence.

Additionally, the implications of these findings extend beyond the clinical realm and into public health policy. Decision-makers must consider these insights when designing and funding cancer screening initiatives. By addressing the social determinants of health and implementing community-based support structures, it is possible to create an environment that encourages sustained adherence to lung cancer screening. This shift in approach could significantly impact mortality rates, ultimately saving thousands of lives.

Considering the trajectory of lung cancer diagnosis and treatment, it is vital that we do not lose sight of the larger context. The emergence of advanced treatment options for lung cancer presents both hope and complexity in patient care. However, without a robust foundation of early detection, the benefits of these innovations may not reach the patients who need them most. The study highlights an essential truth: adherence to screening must be viewed not as a standalone issue but as part of a holistic approach to lung cancer prevention and care.

Moreover, the role of technology in enhancing screening adherence should not be underestimated. With the rise of telehealth and digital health tools, opportunities abound for facilitating patient engagement. Innovative solutions such as reminder systems, educational apps, and virtual consultations can bolster adherence rates, making screenings more accessible and less intimidating for patients. As we embrace these advancements, healthcare professionals must strive to leverage technology in ways that effectively bridge the gaps in patient knowledge and accessibility.

At the core of any successful cancer screening program lies the need for a collaborative approach. Engagement from oncologists, radiologists, primary care providers, and public health officials is paramount. By fostering a multidisciplinary framework, there is a higher likelihood of achieving a collective goal: improved screening rates and, consequently, reduced lung cancer mortality. Shared responsibility within the healthcare community can create a ripple effect, sparking initiatives that challenge the status quo and prioritize patient outcomes.

In contemplating the future of lung cancer screening, the findings of this study serve as a clarion call to action. By addressing the barriers to adherence, enhancing communication with patients, and employing innovative technologies, there is a tangible opportunity to pave the way for a new era of lung cancer prevention. Failure to act could result in missed opportunities for countless individuals whose lives could be saved through timely intervention.

Ultimately, this research is not just about numbers. It is about human lives, the real stories behind diagnoses, and the relentless pursuit of health equity. The study’s insights compel us to reflect on our collective responsibility to foster a healthcare environment where every individual understands the importance of screening and feels empowered to advocate for their health. It is an urgent reminder that our commitment to lung cancer screening must go beyond mere compliance; it must engage, educate, and inspire.

As this research continues to resonate across the medical community, we hope it ignites a dialogue that leads to tangible changes in how lung cancer screening is approached. The message is clear: sustained adherence is not just a metric—it is a lifeline. Healthcare systems, providers, and patients must work together to ensure no one is left behind in the fight against lung cancer.

By taking proactive steps to enhance screening adherence, we honor our responsibility to future generations. The potential for breakthroughs in early detection and treatment lies within our grasp if we commit to making lung cancer screening an integral part of the healthcare landscape. Let us seize this moment to create a brighter future for lung cancer patients everywhere.

Through ongoing research and innovation, combined with a commitment to accessibility and education, we have a unique opportunity to transform lung cancer screening practices. The findings from this multicenter cohort study serve as a testament to what is possible when we focus on adherence as a critical metric of success. May it inspire action that leads to meaningful change in the fight against one of the deadliest cancers.

Subject of Research: Lung cancer screening adherence and detection rates
Article Title: Adherence in Lung Cancer Screening: A Quality Metric that Matters
News Publication Date: [Not provided in the original content]
Web References: [Not provided in the original content]
References: [Not provided in the original content]
Image Credits: [Not provided in the original content]
Keywords: Lung cancer, cancer screening, cohort studies, adherence, early detection, public health, healthcare equity, patient engagement.